胆道癌治疗选择：医生和患者视角下的未满足需求、新靶点和机遇

数据集获取（Figshare）

• 源站标题：Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians’’ and patients’’ perspectives
• DOI：10.6084/m9.figshare.26935920.v1
• 发布日期：2024-09-04
• 文件数：2 个
• 文件总体积：468.76 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Treatment_options_for_biliary_tract_cancer_unmet_needs_new_targets_and_opportunities_from_both_physicians_and_patients_perspectives/26935920

命令行下载

curl -L -o "ifon_a_2340959_sm0001.docx" "https://ndownloader.figshare.com/files/49000299"
curl -L -o "ifon_a_2340959_sm0002.pdf" "https://ndownloader.figshare.com/files/49000302"

文件清单

• ifon_a_2340959_sm0001.docx（21.64 KB）
• ifon_a_2340959_sm0002.pdf（447.12 KB）

文件总体积 468.76 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Biliary tract cancer (BTC) is a rare cancer with poor prognosis, characterized by considerable pathophysiological and molecular heterogeneity. While this makes it difficult to treat, it also provides targeted therapy opportunities. Current standard-of-care is chemotherapy ± immunotherapy, but several targeted agents have recently been approved. The current investigational landscape in BTC emphasizes the importance of biomarker testing at diagnosis. MDM2/MDMX are important negative regulators of the tumor suppressor p53 and provide an additional target in BTC (∼5–8% of tumors are MDM2-amplified). Brigimadlin (BI 907828) is a highly potent MDM2-p53 antagonist that has shown antitumor activity in preclinical studies and promising results in early clinical trials; enrollment is ongoing in a potential registrational trial for patients with BTC.
Biliary tract cancer (BTC), an umbrella term for a number of tumor sub-types, is a rare cancer with a poor prognosis (5-year survival rate: 15% [1]).
It is characterized by considerable pathophysiological and molecular heterogeneity, making it difficult to treat, but providing a number of potentially targetable genetic alterations.
No targeted agents are approved in the first-line setting for patients with BTC; chemotherapy-based regimens with or without immunotherapy are the standard of care.
Clinical trials into alternative immunochemotherapy regimens and FGFR2 inhibitors are ongoing, which may impact on first-line treatment options in the future.
Second-line treatment options are largely chemotherapy-based for patients without targetable mutations, or targeted agents against FGFR2, IDH1, HER2, BRAF V600E, NTRK, DNA damage repair genes, KRAS and RET aberrations, some of which are investigational.
MDM2 is an endogenous negative regulator of p53, hence aberrations of the MDM2 gene can result in inappropriate silencing of wild-type p53, potentially leading to tumorigenesis.
MDM2 amplification is observed in ∼5–8% of BTCs; TP53 mutations are largely mutually exclusive.
MDM2–p53 antagonists are in clinical development for the treatment of various hematologic and solid tumors.
Brigimadlin, an MDM2–p53 antagonist currently

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.26935920.v1（source: https://tandf.figshare.com/articles/dataset/Treatment_options_for_biliary_tract_cancer_unmet_needs_new_targets_and_opportunities_from_both_physicians_and_patients_perspectives/26935920）。